Taysha Gene Therapies (NASDAQ:TSHA) is discontinuing development of its drug candidate TSHA-120 for the treatment of giant axonal neuropathy due to problems designing a study that could support a potential FDA market application.
The biotech group said it is pursuing external strategic options for the program that could enable further development of the drug. It added that Astellas Gene Therapies has elected not to exercise its option to obtain an exclusive license to TSHA-120.
Taysha said discontinuation of the program will extend its cash runway into Q4 2025 and will help support the development of TSHA-102 for the treatment of Rhett syndrome.
TSHA-120 was in Phase 2 testing, according to Taysha’s website.